. 2016 Oct 28;7(48):79761–79773. doi: 10.18632/oncotarget.12962

Table 1. Cell cycle distribution after treatment of Cos, Dehy, C+2D or VOSL for 48 h.

Cell lines	Treatment	Concentration	G0/G1 (%)	S (%)	G2/M (%)
SMMC-7721	Control		63.22±2.62	28.57±1.97	8.21±0.67
	Cos	IC10	59.43±0.62	33.85±0.59 ^*	6.72±1.00
		IC30	50.71±0.73 ^**	39.44±0.60 ^**	9.86±0.15
		IC50	41.77±0.30 ^***	51.01±0.22 ^***	7.22±0.33
	Dehy	IC10	62.88±0.37	30.84±0.61	6.28±0.48
		IC30	55.57±0.83 ^**	35.89±0.66 ^*	8.54±1.30
		IC50	49.44±0.90 ^*	46.22±0.94 ^***	4.34±1.18 ^***
	C+2D	IC10	63.91±1.52	31.25±0.89	4.84±1.23 ^*
		IC30	53.26±0.39 ^**	37.86±0.94 ^**	8.88±0.84
		IC50	45.62± 0.72 ^***	48.57±0.45 ^***	5.80±1.09 ^*
	VOSL	IC10	62.67±1.55	29.84±0.70	7.42±0.96
		IC30	57.99±1.69 ^*	34.09±0.29 ^**	7.91±1.96
		IC50	54.96±1.68 ^**	41.12±1.45 ^***	3.92±0.46 ^*
Hep3B	Control		67.44 ±1.35	24.45±1.18	8.11±0.30
	Cos	IC10	65.85±3.14	25.41±1.06	8.74±3.29
		IC30	59.54±1.29 ^**	34.35±2.23 ^**	6.11±2.82
		IC50	49.71±2.09 ^***	46.93±1.29 ^***	3.36±2.05^*
	Dehy	IC10	64.47±3.62	26.14±0.86	9.40±3.25
		IC30	60.16±2.34 ^**	36.01±2.16 ^**	3.83±2.92
		IC50	34.83±1.74 ^***	46.90±1.08 ^***	18.27±1.77 ^***
	C+2D	IC10	64.88±2.14	29.31±0.67 ^**	5.81±2.19
		IC30	44.51±3.00 ^***	36.22±0.95 ^***	19.27±2.10 ^***
		IC50	32.72±0.82 ^***	48.73±1.15 ^***	18.54±1.46 ^***
	VOSL	IC10	53.43±0.74 ^***	27.92±1.65 ^*	18.65±1.03 ^***
		IC30	57.56±1.68 ^**	35.11±1.67 ^***	7.34±1.63
		IC50	33.55±0.64 ^***	43.78±1.25 ^***	22.68±1.48^***

Note:

p < 0.05,

^**

p < 0.01 and

^***

p < 0.001 compared with the corresponding control group.